ESMO Open

Article	Citations
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors	276
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches	246
PP075 Xia Yuxue decoction inhibits hepatocellular carcinoma metastasis by reducing the abundance of the tumor-resident bacterium Brachybacterium sp.	166
PP153 A randomized, open-label phase ii study comparing a novel regimen of dose-dense docetaxel-cyclophosphamide alternating with epirubicin-cisplatin against anthracycline-taxane in early TNBC, strat	161
PP002 Unravelling the effects of bisphenol A on colorectal cancer progression in obese Sprague-Dawley rats	138
PP175 Unexpected high frequency of pathogenic germline variant (rs34804482, NM_018490.3: c.2531A>G) of the LGR4 gene in Tuvan ethnic group from West Siberia	137
140P Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study	128
35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations	120
130P Progesterone receptor (P) status and survival outcomes of ER-negative breast cancer: A population-based cohort study	115
2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology	112
137P PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts	107
6P An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the screening of ovarian cancer	102
Table of Contents	99
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced	96
97P Drug sensitivity prediction based on RNA expression profiling in colorectal cancer organoids	95
Table of Contents	91
Table of Contents	90
ESMO	90
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines	86
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap	81
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study	80
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles	76
76P Relative dose-intensity of trabectedin and outcome of advanced L-sarcomas	74
115P Impact of clinical and treatment factors on trabectedin toxicity in soft tissue sarcomas	74
50P Combination of platinum-based chemotherapy with immunotherapy in treatment of extrapulmonary neuroendocrine carcinoma: A retrospective study	69

143P Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: A cross-sectional study of published trials between 2015 and 2024	68
Total pain, opioids, and immune checkpoint inhibitors in the survival of patients with cancer	66
58P Peripheral T cell phenotypes as predictors of progression and treatment response in mCRC: A prospective immunoprofiling study	65
8P Unveiling functional reprogramming in pancreatic cancer: An integrative transcriptomic and explainable machine learning approach	60
Induction immunotherapy plus chemotherapy for Pancoast lung cancer tumors: are we ready to shift our standards?	59
36P Next-generation sequencing in liquid biopsy for advanced NSCLC: Indian tertiary cancer centre experience	58
Equitable inclusion of diverse populations in oncology clinical trials: deterrents and drivers	58
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMAN	57
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single	57
Olaparib as a rescue treatment in platinum-refractory germ-cell tumors: the IGG-02 phase II trial	57
Response to: The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)	54
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cance	54
338P Real-world progression-free survival (PFS) and overall survival (OS) for advanced breast cancer (aBC) treated with ribociclib (RIB) in the RIBANNA trial	53
22P PillPal.ai: Using artificial intelligence to improve adherence to oral chemotherapy, TKIs, and CDK4/6 Inhibitors - A pilot study from a tertiary cancer centre in India	52
Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes	52
83P Efficacy and safety of KRAS G12C inhibitors across solid tumors: A systematic review and meta-analysis	50
16eP Efficacy and safety of bevacizumab biosimilar in the treatment of brain metastases from breast cancer: A prospective, single-arm, multicentre, real-world study	50
Systemic anticancer therapy near the end of life: an analysis of factors influencing treatment in advanced cancer patients	49
An innovative model of delivering cancer care in the community: the experience of a tertiary cancer centre in Singapore	49
Palbociclib combined with endocrine treatment in hormone receptor-positive, HER2-negative breast cancer patients with high relapse risk after neoadjuvant chemotherapy: subgroup analyses of premenopaus	48
152P Pregnancy after gestational trophoblastic neoplasia: Navigating fertility post-chemotherapy	48
Concurrent antibody–drug conjugates and radiotherapy: a new perspective on radiation necrosis in HER2-positive breast cancer brain metastases from the DESTINY-Breast03 and HER2CLIMB trials	48
43eP Is age a risk factor for locally advanced cervical cancer persistence?	48
Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)]	48
225P Impact of cyclin inhibitors (CDK4/6i) on immune cell populations in first-line treated metastatic breast cancer (mBC) patients	47
90P Effect of atirmociclib plus endocrine therapy (ET) on serum thymidine kinase activity (TKa) in a phase I study of patients with HR+/HER2− metastatic breast cancer (mBC)	47
PP474 Isoliensinine enhances therapeutic efficacy of paclitaxel and induces mitochondria-mediated cell death in multidrug-resistant colon cancer stem cells	47
71P Relapse rate in patients avoiding adjuvant chemotherapy based on Oncotype DX score: Real-world data from three UK centres	46
148P AI driven adjuvant therapy: Predicting pCR from radiological data in patients receiving incomplete NACT for LABC	46
307P Relationship between physician-graded symptomatic adverse events and patient-reported quality of life (QOL): An analysis of the phase III PALLAS trial	44
211P Risk of recurrence (ROR) among patients (pts) with HR+/HER2− early breast cancer (EBC) involving 1-3 axillary lymph nodes (N1): A real-world evaluation	44
393P Treatment outcomes and toxicity of palbociclib in metastatic hormone receptor (HR)-positive HER2 -ve breast cancer patients: Real-life palbociclib outcome in Omani patients	43
420P Physicians’ knowledge, practice and attitudes on fertility and pregnancy-related issues in young women with advanced breast cancer: Results of the ABC6 and ABC7 survey	43
412TiP HEROES: De-escalation of medical therapies in HER2-positive metastatic breast cancer in long-term persistent response and minimal residual disease undetectable in circulating tumor DNA	43
238P Comparing the benefit-risk profiles of emerging treatments in early breast cancer (eBC) using the ESMO MCBS and the ASCO value framework	42
357P BRCA genetic testing implementation and the impact of BRCA pathogenic variant status on clinical outcomes in HER2-negative metastatic and recurrent breast cancer in Japan	42
334P The nationwide Advanced Breast Cancer - Patient Care Initiative (ABC-PCI): A medical oncologist-led survey on quality of life in Chinese patients with metastatic triple-negative breast cancer	42
225P The impact of predictive genomic testing in Ireland: Financial and resource implications for healthcare institutions and patients	42
222P Hemoglobin A1c screening for patients with early breast cancer treated with adjuvant endocrine therapy	41
72MO Homologous recombination deficiency (HRD) and genomic subgroup analysis in patients (pts) with platinum-sensitive ovarian cancer (PSOC) receiving mirvetuximab soravtansine-gynx (MIRV) in the PICC	40
48P An AI System for accurate Ki-67 IHC assessment in breast cancer following the IKWG whole section global scoring protocol	40
438P Antidepressants/anxiolytics and breast cancer treatment: The case of drug-drug interactions	40
Unraveling the clinicopathological and molecular changes induced by neoadjuvant chemotherapy and endocrine therapy in hormone receptor-positive/HER2-low and HER2-0 breast cancer	40
Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities	39
SWI/SNF family mutations in advanced NSCLC: genetic characteristics and immune checkpoint inhibitors’ therapeutic implication	39
Treatment-related adverse events as predictive biomarkers of efficacy in patients with advanced neuroendocrine tumors treated with surufatinib: results from two phase III studies	38
Letter comments on: Drug–drug interactions between palbociclib and proton pump inhibitors may significantly affect clinical outcome of patients with metastatic breast cancer	38
97P Cost-effectiveness of TTFields in addition to standard systemic therapy for stage IV non-small cell lung cancer patients following progression on or after platinum-based chemotherapy	38
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study	38
164P Circulating cytokines levels as predictive biomarkers in pleural mesothelioma: Preliminary data from a prospective translational study	37

175P Quality of life in patients with NSCLC brain metastases undergoing different local therapies in the era of precision oncology: A territory-wide study	37
38P Real-world treatment patterns and effectiveness of subsequent treatments following first-line (1L) brigatinib for patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cance	36
Editorial Board	36
51O The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group	36
199P Radiomics analysis predicts chemoimmunotherapy advantage over chemotherapy alone in extensive-stage small cell lung cancer (ES SCLC)	36
Editorial Board	36
200P OlympiAD: Exploratory analysis of olaparib vs capecitabine in patients with germline BRCA-mutated (gBRCAm) metastatic breast cancer (mBC)	35
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot	35
94P Efficacy of first-line pembrolizumab in elderly patients with advanced non-small cell lung cancer with high PD-L1 expression	35
39P A validation study of a self-testing capillary kit, the rhelise kit for therapeutic dose monitoring (TDM) of tamoxifen, Z-endoxifen, and 4-hydroxytamoxifen in breast cancer patients	35
87P Characteristics and outcomes of 11 patients with myoepithelial tumors: The Gustave Roussy experience	34
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials	34
Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results	34
47P Sarcoma in the Czech Republic: Update data through 2021 including epidemiology, patients flow and treatment outcomes	34
62P Updated overall survival and safety with ripretinib vs sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib and harboring KIT exon 11 + 17/18 mutatio	34
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom	34
144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy	33
142P The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer	33
146P The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis	33
148P Identification of potential predictive biomarkers for ovarian cancer chemotherapy response	32
8P Clinicopathological features and the role of adjuvant therapy in the management of gastrointestinal verrucous carcinoma	31
10P The risk of second primary lymphoma in colorectal cancer: An updated SEER analysis 2000–2020	31
74P Obesity regulates tumor progression and sensitivity to checkpoint blockade through the diet-microbiota-immunity axis	31
128P Innovative limb salvage: Liquid nitrogen approach in reconstruction after bone tumor resection	31
83P Cost-effectiveness analysis of talazoparib maintenance treatment for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US	31
129P FDG PET imaging of symptomatic chest wall myositis following stereotactic body radiation therapy (SBRT) for patients with early stage cell lung cancer	31
63P Activity and safety of FGFR inhibitors in pan-cancer patients with FGF/FGFR alterations and advanced malignancies: A pooled analysis of 7 phase I/II trials	31
Editorial Board	30
103P MSI detection by NGS using tumor samples and liquid biopsy for patients with solid tumors: A single institution experience	30
PP049 Redistribution of 8-oxo-G/AP sites hot spots mediated transcription alteration is a novel and ubiquitous mechanism in EGFR-TKI resistance of NSCLC	30
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling	30
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer	29
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations	29
Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX	29
Editorial Board	29
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma	29
OP27 A phase II study of neoadjuvant erlotinib for operable stage II or IIIA non-small cell lung cancer with epidermal growth factor receptor activating mutations	29
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)	28
22P Emerging role of histone acetyltransferase CBP in breast cancer cells undergoing DNA damage	28
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?	28
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas	28
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib	28
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study	28
27O First-in-class first-in-human phase I trial of RBN-2397 in patients with advanced solid tumors validates PARP7 as a novel anticancer therapeutic target	28
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study	27
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada	27
Corrigendum to “Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients	27
185O Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): A detailed safety analysis of the rando	27
55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells	27
70P Development and validation of a machine learning (ML) nomogram to predict RSClin results and guide adjuvant treatment of node-negative (N0) hormone receptor-positive (HR+)/human epidermal growth f	27
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study	26
Vaccination for seasonal influenza, pneumococcal infection and SARS-CoV-2 in patients with solid tumors: recommendations of the Associazione Italiana di Oncologia Medica (AIOM)	26
HER2DX in HER2-positive inflammatory breast cancer: correlative insights and comparative analysis with noninflammatory breast cancers	26
Palbociclib exposure in relation to efficacy and toxicity in patients with advanced breast cancer	26
Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer	25
Oncology professionals’ perceptions and recommendations to improve well-being and health at work in times of crisis: qualitative thematic analysis from the ESMO Resilience Task Force survey series	25
Zanidatamab in combination with docetaxel in first-line HER2-positive breast cancer: results from an open-label, multicenter, phase Ib/II study	25
Evolving therapeutic landscape of advanced biliary tract cancer: from chemotherapy to molecular targets	24
A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)	24
Determining fitness for enfortumab vedotin and pembrolizumab in metastatic bladder cancer: the time to move beyond isolated comorbidity assessments	24
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)	24
Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: developme	24
Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe	24
2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting	24
Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial	24
Implementing SERENA6 in the clinic in the UAE: critical thinking of a community oncologist	24
Comments on ‘Biomarkers of systemic inflammation predict survival with first-line immune checkpoint inhibitors in non-small-cell lung cancer’	24
6P vAO - Variant Annotator for OncoKB: A simplified interface to identify targeted therapies for somatic tumors	23
131P Symptoms, fear of cancer recurrence and supportive care needs in gastrointestinal stromal tumor patients undergoing targeted therapy	23
Corrigendum to ‘A phase II trial of paclitaxel plus biweekly cetuximab for patients with recurrent or metastatic head and neck cancer previously treated with both platinum-based chemotherapy and anti-	23
23P Anti-tumor activity of novel Globo-H targeting CAR T cells in cholangiocarcinoma model	23
Psychiatric disorders in adolescent and young adult cancer survivors in Korea	23
108P Biomarkers and personalized cancer therapy: A study of trial discontinuation and unpublished rates	23
487P Health care provider’s adherence to clinical practice guidelines in diagnosing and staging breast cancer: An observational study	22
273P Clinicopathological features and outcomes in patients with BRCA-associated HR+/HER2- breast cancers eligible for adjuvant CDK4/6 and PARP inhibitors	22
301MO Primary efficacy results of tremelimumab and durvalumab in combination with trastuzumab in trastuzumab resistant advanced HER2-positive breast cancer: BCT1703 DIAmOND	22
283P Incidence of male breast cancer in genetically high-risk patients	22
398P Evaluation of trastuzumab deruxtecan for metastatic HER2+ breast cancer: A meta-analysis	22
7P Unveiling the prognostic significance of protein expression in advanced high-grade serous ovarian cancer: A comparative study between long-term survivors and early mortal patients	22
439P The bio-psycho-social predictors of mental health among women with breast cancer	22

220P Efficacy and saftey of neoadjuvant trastuzumab, pyrotinib and chemotherapy in HER2-positive breast cancer: A real-world study	22
430P Analysis of quality of life in a group of very long-term early stage breast cancer survivors	22
481P Trends in mortality due to malignant and benign breast neoplasms in the United States from 2018 to 2023: A CDC wonder analysis	22
246P Four years of Oncotype DX test in clinical practice: the experience of the breast unit of University Hospital of Parma	22
229P Risk of recurrence and overall survival in Stage II and III ER+/HER2- early breast cancer: A population-based registry study in Sweden	22
136P Vascular endothelial growth factor A (VEGF-A) expressions in invasive breast cancer and its association with lymph node metastasis and histopathologic features	21
178P Comparative study between wise pattern and non-vertical scar reduction mammoplasty	21
24P The role of radiotherapy for intermediate-risk in early-stage cervical cancer post-radical hysterectomy: A meta-analysis	21
120P Genetic associations of plasma proteins and breast cancer: Potential therapeutic drug candidates	21
134P Gene alterations in Mongolian breast cancer patients	21
85P Niraparib customized dosing regimen (RADAR) to manage thrombocytopenia events in platinum-sensitive recurrent ovarian cancer patients: The NEWTON trial	21
21P Squamous cell carcinoma arising from germ cell tumour of the ovary treated with immunotherapy	21
56P Neoadjuvant treatment with sequential letrozole and exemestane in postmenopausal patients with HR-positive, HER-2 negative breast cancer: Clinical and biomarker outcomes from the NEOLETEXE trial	21
53P Tumor-agnostic detection and monitoring of circulating tumor DNA in HER2-positive early-stage breast cancer	21
37eP Local control with chemoradiotherapy in patients with metastatic cervical cancer	21
Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study	21
154P Alternative splicing in non-small cell lung cancer evolution	20
153P Discovery of new BRCA1/2 mutations not described in the international breast consortium	20
108P Unravelling how different treatment sequences affect survival in osteosarcoma patients: A population-based study	20
Cholangiocarcinoma patients with FGFR2 fusions/rearrangements but primary refractory to pemigatinib: the real challenge?	20
152P Nanopore sequencing of cfDNA captures key copy number alterations in lung adenocarcinoma: A non-invasive approach for prognosis, therapy, and subtyping	20
44P Reintroduction of platinum-based chemotherapy ± mitotane for advanced adrenocortical cancer: Single-center retrospective trial	20
73P TROP2 amplification is highly present in dedifferentiated liposarcoma: Data from the Cancer Genome Atlas (TCGA) in soft tissue sarcoma	20
94P Clinical utility of long read sequencing for comprehensive analysis of cancer patient genomes	20
Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis	20
59P Delay in diagnosis of soft tissue sarcoma (STS): Contributing factors and their impact on overall survival - Experience from a tertiary care hospital	20
272P Evaluating a digital tool for supporting people affected by breast cancer: A prospective randomised controlled trial - The ADAPT study	19
224P Efficacy of single-agent second-line fulvestrant (FUL) in metastatic invasive lobular carcinoma (mILC) exposed to first-line aromatase inhibitors (AI) and cyclin-dependent kinase 4 and 6 inhibito	19
233P Real-world first-line (1L) treatment selection for Australian patients (pts) with hormone receptor-positive advanced breast cancer (HR+ ABC)	19
Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phas	19
54P Comparison of ctDNA profiles in lobular vs NST hormone receptor-positive metastatic breast cancer patients in early lines of treatment	19
296P Management of sexual dysfunction in breast cancer survivor women on adjuvant therapy	19
297P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective	19
MAP 2025 Officers and Organisation	19
142P Exploring 18F-FDG PET as a predictior of immune-related adverse events (irAEs) in early-stage triple-negative breast cancer (eTNBC)	19
Editorial Board	19
30P Novel integrated tumor micro-/macro-environment (TMME) subtypes for prediction of treatment response to neoadjuvant anti-HER2 therapy	19
65eP Real-world impact of pembrolizumab plus lenvatinib in metastatic uveal melanoma: A retrospective multicenter study	19
93P Intra- and post-operative management of sentinel lymph node micrometastasis and prognosis analysis in patients with breast cancer from southern China: A multicenter, retrospective, real-world stud	19
Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A	18
Therapeutic benefit of larotrectinib over the historical standard of care in patients with locally advanced or metastatic infantile fibrosarcoma (EPI VITRAKVI study)	18
Table of Contents	18
76P Circadian control of neutrophil extracellular trap formation temporally regulates metastatic lung cancer progression	18
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer:	18
127O Response to TIL therapy depends on a tumor-intrinsic IL-2 signaling axis that drives expansion of CD25+ tumor-reactive T cells	18
17eP Fitzpatrick-guided AI system for ABCD-based dermoscopic analysis and melanoma risk stratification	18
33P Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models	18
5MO Effect of amivantamab dose interruptions on efficacy and safety of first-line amivantamab plus lazertinib in EGFR-mutant advanced NSCLC: Exploratory analyses from the MARIPOSA study	18
Efficacy of tyrosine kinase inhibitors for the treatment of patients with HER2-positive breast cancer with brain metastases: a systematic review and meta-analysis	18
124P Melittin inhibits the growth of hepatocellular carcinoma Huh7 cells by downregulating LARS2 and ZNF19	18
74P Evaluation of the clinical significance of rare epidermal growth factor receptor exon 19 insertion-deletion variants on tyrosine kinase inhibitor efficacy in non-small cell lung cancer: A five-yea	18
70eP Decoding ambiguity of variants of uncertain significance (VUS) of non-small cell lung carcinoma (NSCLC) using a comprehensive NGS panel: Landmark study from an Indian cohort	18
57P Multi-matrix untargeted metabolomics profiling reveals potential non-invasive prognostic and predictive biomarkers in metastatic colorectal cancer: The CRC-Tsen study	18
268MO Safety of vaginal estrogen therapy after early-stage breast cancer: A nationwide population-based target trial emulation	18
147P Population-adjusted indirect comparisons of repotrectinib and entrectinib in ROS1+ locally advanced or metastatic non-small cell lung cancer (NSCLC)	18
Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety trial of trastuzumab emtansine in patients with HER2-positive advanced breast cancer	18
Immunotherapy for resectable NSCLC: neoadjuvant/perioperative followed by surgery over surgery followed by adjuvant. Systematic review and meta-analysis with subgroup analyses	18
45P Phenotypic diversity of lynch syndrome and the role of NGS in its molecular characterization	18
17P Efficacy and safety of furmonertinib as salvage treatment for EGFR-mutated NSCLC patients progressed on third-generation EGFR TKIs	17
208P The discrepancies between real-world evidence and clinical trials: A study investigating stage IV SCLC	17
132P Novel small molecule modulators for activation of mutant tumor suppressor p53	17
PP065 In silico genetic polymorphisms analysis of GSTP1 and their effect on platinum compound and antituberculosis drugs co-medication in lung cancer patients with tuberculosis comorbidity	17
79P Real-world comparative analysis of liposomal doxorubicin and paclitaxel in first-line treatment of Kaposi sarcoma: A retrospective study in Brazil	17
18P AURKB inhibition radiosensitises NSCLC by altering mitotic fate	17
90P Is physician-patient language concordance better for clinical trial enrollment in breast cancer patients? A real-life study	17
52P Liquid biopsy monitoring in BRAF V600E mutated NSCLC patients treated with dabrafenib plus trametinib: A prospective, explorative, multicentric study, LiBRA study (GOIRC-03-2020)	17
54P Efficacy of first-line immunotherapy for non-small cell lung cancer with MET exon 14 skipping according to PD-L1 expression	17
89P Immune homeostasis mediators and disease progression in chemotherapy-naïve and neoadjuvant chemotherapy treated gastric cancer patients	17
PP064 MicroRNA 200c-3p targeting CDH1 gene polymorphism towards risk susceptibility of prostate cancer in North Indian population	17
142P Role and impact of hypoxia-inducible factor 1-alpha on survival rates in pancreatic cancer: A systematic review and meta-analysis	17
PP499 3-weekly daratumumab-based quadruplet induction regimen is highly effective in newly diagnosed multiple myeloma	17
252P Characterization of sexual dysfunction in women with lung cancer: Update of the CLARIFY project	17
16P A phase Ib/II trial to evaluate safety and efficacy of aurora kinase inhibitor LY3295668 in combination with osimertinib for patients with EGFR-mutant non-small cell lung cancer	17
46P The role of microRNA-1246 in early detection of breast cancer: Findings from a systematic review and meta-analysis	17
153P BRAF variants and therapy outcomes in melanoma	17
29P First-line of camrelizumab, apatinib mesylate and chemotherapy for advanced high-grade neuroendocrine tumors (NETS): A single center, single arm, exploratory study	17
45P Integrative analysis of TCGA DNA methylation, RNA-sequencing, and variant dataset using machine learning in predicting endometrial cancer recurrence	17
161P DESCARTES trial: De-ESCAlating RadioTherapy in patients with pathologic complete response to neoadjuvant systemic therapy	17
114P Effects of chemotherapy on TREG lymphocytes in early breast cancer	17
OP28 Cost-effectiveness analyses of durvalumab consolidation therapy compared to no consolidation therapy after definitive chemoradiotherapy in stage III NSCLC	16
58P The lymphocyte activation gene-3 (LAG-3) protein expression in tumor-infiltrating lymphocytes is associated with a poor prognosis of ovarian clear cell carcinoma	16
77P The impact of COVID-19 on gynecological cancer diagnoses in Greece	16
83P Radiological evaluation of response in patients with soft tissue sarcoma treated with trabectedin	16
PP108 Is it possible to avoid seroma after mastectomy and axillary lymph node dissection using microporous polysaccharide hemispheres (AristaTM)?	16
108P Establishing a multi-modal tissue preparation and imaging workflow to study heterogeneity in neuroblastoma tumors	16
11P Conization before radical hysterectomy in early cervical cancer: A Korean multi-center study	16
80P Efficacy, FDA approval, innovativeness, clinical evidence, and price of breast, ovarian, endometrial, and cervical cancer drugs	16
96P Age-adjusted trends and survival analysis of alveolar soft part sarcoma	16
117P Merkel cell carcinoma: Epidemiological pattern in the United States, a SEER based study	16
139P Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: A systematic review and network meta-analysis	16
18P PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response	16
14P Unravelling the immune landscape of non-epithelial ovarian cancer	16
PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers	15
243P Identifying the communication needs of people living with metastatic breast cancer (MBC) in Ireland: An all-Ireland patient-led survey (CTRIAL-IE 23-05)	15
Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study	15